GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.
BofA Adds Booz Allen Hamilton and Datadog to Its US 1 List
Live Stock News: Market Waiting to See if the President Says Something Exciting Today
Sales are disappointing, and the market scale is questionable....... The trade of overseas weight-loss drug stocks is cooling down.
Due to disappointing clinical trial results for new drugs and sales data below expectations for two consecutive quarters, the stock prices of Novo-Nordisk A/S and Eli Lilly and Co have fallen from their historical highs. Novo-Nordisk A/S has missed out on the top spot in the European stock market, and stocks related to weight loss drugs have entered bear market territory.
Wall Street Today: Does Anyone Have the Cash for Stargates
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate